NYSE:OGEN Oragenics (OGEN) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free OGEN Stock Alerts $1.42 +0.02 (+1.07%) (As of 03:12 PM ET) Add Compare Share Share Today's Range$1.40▼$1.4750-Day Range$1.38▼$6.1452-Week Range$1.26▼$7.74Volume20,525 shsAverage Volume87,437 shsMarket Capitalization$6.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Oragenics alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About OragenicsOragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More OGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OGEN Stock News HeadlinesMarch 23, 2024 | americanbankingnews.comOragenics (NYSE:OGEN) Receives New Coverage from Analysts at StockNews.comMarch 18, 2024 | markets.businessinsider.comOragenics Appoints Kelly As Chief Medical OfficerMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 17, 2024 | finance.yahoo.com15 Highest Quality Probiotics For Gut HealthMarch 5, 2024 | businesswire.comOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionMarch 1, 2024 | businesswire.comOragenics Announces Closing of Public OfferingMarch 1, 2024 | uk.investing.comOragenics announces public stock offeringFebruary 28, 2024 | investorplace.comWhy Is Oragenics (OGEN) Stock Down 45% Today?March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… February 27, 2024 | markets.businessinsider.comOragenics Prices Public Offering Of 1.40 Mln Shares At $1.50/shr; Stock PlungesFebruary 27, 2024 | businesswire.comOragenics Announces Pricing of Public OfferingFebruary 27, 2024 | marketwatch.comOragenics Shares Fall After Proposed Public OfferingFebruary 27, 2024 | businesswire.comOragenics Announces Proposed Public OfferingFebruary 12, 2024 | marketwatch.comOragenics CEO Murphy Leaves, President Redmond Named Interim ReplacementFebruary 12, 2024 | finance.yahoo.comOragenics, Inc. Announces Leadership TransitionFebruary 7, 2024 | finance.yahoo.comOragenics, Inc. Announces Expiration of Its Investment Banking Engagement AgreementFebruary 5, 2024 | finance.yahoo.comOragenics, Inc. Preparing for Phase II Clinical Trials to Treat ConcussionJanuary 23, 2024 | msn.comOragenics terminates ATM offering program; shares jumpJanuary 23, 2024 | finance.yahoo.comOragenics Announces Termination of At-The-Market Offering ProgramJanuary 6, 2024 | seekingalpha.comOGEN, RLMD and ATXI among mid-day moversJanuary 2, 2024 | financialpost.comOragenics Completes Acquisition of Odyssey Health’s Neurological AssetsDecember 12, 2023 | finanznachrichten.deOdyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.November 6, 2023 | finance.yahoo.comOragenics, Inc. (UAV.F)November 2, 2023 | finance.yahoo.comOragenics Issues Update to ShareholdersOctober 5, 2023 | marketwatch.comOragenics Shares Rise 15% After Deal to Buy Some Odyssey Health AssetsOctober 5, 2023 | finance.yahoo.comOragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug CandidateOctober 2, 2023 | msn.comOragenics, AVITA Medical among healthcare moversSee More Headlines Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2021Today3/28/2024Next Earnings (Estimated)4/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net MarginsN/A Pretax Margin-26,700.00% Return on Equity-132.48% Return on Assets-93.84% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$130,000.00 Price / Sales48.25 Cash FlowN/A Price / Cash FlowN/A Book Value$5.64 per share Price / Book0.25Miscellaneous Outstanding Shares4,480,000Free Float3,379,000Market Cap$6.27 million OptionableN/A Beta0.29 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Charles L. Pope CPA (Age 72)Executive Chairman Comp: $82.5kMr. Joseph Michael Redmond (Age 63)President & Interim Principal Executive Officer Ms. Janet Huffman (Age 52)CFO, Secretary & Treasurer Dr. James P. Kelly M.A.M.D., Chief Medical Officer & Member of Scientific AdvisorKey CompetitorsSoligenixNASDAQ:SNGXGT BiopharmaNASDAQ:GTBPPulmatrixNASDAQ:PULMSonnet BioTherapeuticsNASDAQ:SONNKinetaNASDAQ:KAView All CompetitorsInsidersFred TellingSold 3,500 sharesTotal: $12,495.00 ($3.57/share)View All Insider Transactions OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed in 2024? Oragenics' stock was trading at $6.1382 at the beginning of the year. Since then, OGEN shares have decreased by 77.0% and is now trading at $1.41. View the best growth stocks for 2024 here. When is Oragenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, April 12th 2024. View our OGEN earnings forecast. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSE:OGEN) posted its earnings results on Monday, August, 16th. The company reported ($1.80) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $0.60. When did Oragenics' stock split? Oragenics's stock reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ), MFA Financial (MFA) and How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:OGEN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.